Hongsen Investment
Hongsen Investment Group is a venture capital firm established in 2020 and located in Hong Kong. The firm specializes in investing in the pharmaceutical and biotech sectors, focusing on emerging companies that demonstrate innovative potential within these industries. By providing financial support and strategic guidance, Hongsen aims to foster the growth of promising ventures that can contribute to advancements in healthcare and biotechnology.
1 past transactions
Abcuro
Series A in 2021
Abcuro, Inc. is a biotechnology company focused on developing immunotherapies for the treatment of autoimmunity and cancer. Established in 2015 and headquartered in Newton, Massachusetts, Abcuro specializes in creating therapeutic antibodies that target novel pathways in these diseases. The company employs advanced bioinformatics to analyze transcription data from human diseases, enabling them to identify new therapeutic targets within the immune system. By leveraging clinical insights and systematic target validation, Abcuro aims to develop immune-modulatory biotherapeutics that provide innovative treatment options for patients suffering from autoimmune disorders and cancer.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.